KRAS mutation analysis was performed tested in tumor samples collectedfrom over 1000 participants of the “CRYSTAL” [8], “OPUS”[40], NCIC-CO.17 trial [41] and panitumumab trials [42]. Here, KRAS is linked to neoplasm.